Novartis Big Earners Beat Q1 Forecasts
But Disappointing Quarter For Beovu
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
You may also be interested in...
Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?
The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.
Will Beovu Be A Slow-Burning Blockbuster?
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings
Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.